Author(s): Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K,
Abstract Share this page
Abstract We retrospectively examined the frequency of bladder cancer in Japanese patients with type 2 diabetes in relation to use of pioglitazone. Among a total of 663 patients identified to be taking pioglitazone, 9 had bladder cancer (1.36\%). Overall the hazard ratio of 1.75 [95\% CI: 0.89-3.45] for pioglitazone for bladder cancer was not significant. However the prevalence of bladder cancer was 2.10\% in patients taking pioglitazone for less than 24 months which was significant increased (HR 2.73 [95\% CI: 1.11-6.72]). Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.
This article was published in Diabetes Res Clin Pract
and referenced in Medical & Surgical Urology